Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy-Reference-Cited by-同舟云学术

Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy

Published:2018-10 Issue:4 Volume:74 Page:474-480
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Verbiest Annelies^ORCID,Couchy Gabrielle,Job Sylvie,Caruana Laure,Lerut Evelyne,Oyen Raymond,de Reyniès Aurélien,Tosco Lorenzo,Joniau Steven,Van Poppel Hendrik,Van Raemdonck Dirk,Van Den Eynde Kathleen,Wozniak Agnieszka,Zucman-Rossi Jessica,Beuselinck Benoit

Publisher

Elsevier BV

Subject

Urology

Reference33 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Updated European Association of Urology Guidelines Recommendations for the treatment of first-line metastatic clear cell renal cancer;Powles;Eur Urol,2018

3. EAU guidelines on renal cell carcinoma: 2014 update;Ljungberg;Eur Urol,2015

4. Metastasis therapies for renal cancer;Dabestani;Curr Opin Urol,2016

5. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study;Gomez;Lancet Oncol,2016

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and Validation of a 15-Gene Prognostic Signature for Clear Cell Renal Cell Carcinoma;JCO Precision Oncology;2024-05

2. Analysis of the impact of cytoreductive surgery in patients with oligometastatic renal cell carcinoma in clinical practice;Siberian journal of oncology;2024-03-22

3. Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?;Biomedicines;2024-02-07

4. SCGN and STAT3 expressions are associated with the prognosis of ccRCC;Pathology - Research and Practice;2023-12

5. International Multi-institutional Characterization of the Perioperative Morbidity of Metastasectomy for Renal Cell Carcinoma;European Urology Oncology;2023-02